Pancreatic Cancer Clinical Trials & Research at Providence Medical Group
Pancreatic cancer develops in the pancreatic ductal, acinar, and islet
cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal
(PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers
in the U.S. Risk factors that can be changed include tobacco use, obesity,
and workplace exposure to certain chemicals.
Providence Medical Group is currently enrolling patients for the following
pancreatic cancer clinical trial:
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to
Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has
Spread With Inherited BRCA Mutations
Treatment: Pembrolizumab, Olaparib
PI: Yao Yao Pollock, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707)
521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04548752?term=NCT04548752&draw=2&rank=1
Sponsor: National Cancer Institute
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to
Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has
Spread With Inherited BRCA Mutations
Treatment: Pembrolizumab, Olaparib
PI: Yao Yao Pollock, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707)
521-3830 ext. 1181
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04548752?term=NCT04548752&draw=2&rank=1
Sponsor: National Cancer Institute